Division of Population Health Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
BMC Geriatr. 2019 Apr 29;19(1):121. doi: 10.1186/s12877-019-1138-7.
The Drug Burden Index (DBI) quantifies exposure to medications with anticholinergic and/or sedative effects. A consensus list of DBI medications available in Ireland was recently developed for use as a DBI tool. The aim of this study was to validate this DBI tool by examining the association of DBI score with important health outcomes in Irish community-dwelling older people.
This was a cohort study using data from The Irish Longitudinal Study on Ageing (TILDA) with linked pharmacy claims data. Individuals aged ≥65 years participating in TILDA and enrolled in the General Medical Services scheme were eligible for inclusion. DBI score was determined by applying the DBI tool to participants' medication dispensing data in the year prior to outcome assessment. DBI score was recoded into a categorical variable [none (0), low (> 0 and < 1), and high (≥1)]. Outcome measures included any Activities of Daily Living (ADL) impairment, any Instrumental Activities of Daily Living (IADL) impairment, any self-reported fall in the previous 12 months, any frailty criterion met (Fried Phenotype measure), quality of life (QoL) score (CASP-19 [Control Autonomy Self-realisation Pleasure] measure), and healthcare utilisation (any hospital admission and any emergency department (ED) visit) in the previous 12 months. Statistical analyses included multivariate logistic and linear regression models controlling for potential confounders.
61.3% (n = 1946) of participants received at least one DBI prescription in the year before their outcome assessment. High DBI exposure (DBI score ≥ 1) vs none was significantly associated with impaired function (ADL impairment adjusted OR 1.89, 95% CI 1.25, 2.88; IADL impairment adjusted OR 2.97, 95% CI 1.91, 4.61), self-reported falls (adjusted OR 1.50, 95%CI 1.03, 2.18), frailty (adjusted OR 1.74, 95% CI 1.14, 2.67), and reduced QoL (β = - 1.84, 95%CI -3.14, - 0.54). There was no significant association between DBI exposure and healthcare utilisation.
The findings validate the use of the DBI tool for predicting risk of functional impairment, falls, frailty and reduced QoL in older people in Ireland, and may be extended to other European countries. Integration of this tool into routine practice may be an appropriate step forward to improve outcomes in older people.
药物负担指数(DBI)量化了暴露于具有抗胆碱能和/或镇静作用的药物的程度。最近为爱尔兰开发了一种共识清单,其中包含可用于 DBI 工具的 DBI 药物。本研究的目的是通过检查 DBI 评分与爱尔兰社区居住的老年人的重要健康结果之间的关联来验证该 DBI 工具。
这是一项使用爱尔兰老龄化纵向研究(TILDA)的数据进行的队列研究,并与药房理赔数据相关联。符合条件的参与者为年龄≥65 岁且参加 TILDA 并参加普通医疗服务计划的人。DBI 评分是通过将 DBI 工具应用于参与者在结果评估前一年的药物配药数据来确定的。DBI 评分被重新编码为分类变量[无(0),低(>0 且<1)和高(≥1)]。结果衡量标准包括任何日常生活活动(ADL)受损、任何工具性日常生活活动(IADL)受损、过去 12 个月内任何自我报告的跌倒、任何符合虚弱标准(Fried 表型测量)、生活质量(CASP-19[控制自主自我实现愉悦]测量)和过去 12 个月内的任何医疗保健利用(任何住院和任何急诊部(ED)就诊)。统计分析包括控制潜在混杂因素的多变量逻辑和线性回归模型。
在结果评估前一年,61.3%(n=1946)的参与者至少接受了一种 DBI 处方。与无 DBI 暴露(DBI 评分<1)相比,高 DBI 暴露(DBI 评分≥1)与功能受损(ADL 受损调整后的 OR 1.89,95%CI 1.25,2.88;IADL 受损调整后的 OR 2.97,95%CI 1.91,4.61)、自我报告的跌倒(调整后的 OR 1.50,95%CI 1.03,2.18)、虚弱(调整后的 OR 1.74,95%CI 1.14,2.67)和降低的生活质量(β=-1.84,95%CI-3.14,-0.54)显著相关。DBI 暴露与医疗保健利用之间没有显著关联。
这些发现验证了 DBI 工具在预测爱尔兰老年人功能障碍、跌倒、虚弱和降低生活质量风险方面的使用,并可能扩展到其他欧洲国家。将该工具纳入常规实践可能是改善老年人结局的适当步骤。